ClinicalTrialsFinder

Metastatic Castration Sensitive Prostate Cancer (mCSPC) Clinical Trials in Hangzhou, Zhejiang

1 recruitingHangzhou, Zhejiang, China

Showing 1–1 of 1 trials

Recruiting
Phase 3

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled295 locationsNCT07028853